EDG-15400 Updated Jul 13
EDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.
- Novel mechanism targeting diastolic dysfunction directly, if successful, EDG-15400 would be first-in-class as a cardiac sarcomere modulator for HFpEF, a condition with no disease-modifying therapy that specifically targets the underlying mechanical dysfunction
- HFpEF is a massive and growing market (~50% of all heart failure cases, $7.9B heart failure drug market in 2025 projected to reach $21.5B by 2036), and approved therapies like Entresto and SGLT2 inhibitors address it only indirectly
- Edgewise is extremely well-capitalized after the $1.55B upfront from Servier (closed July 2026), eliminating financing risk for EDG-15400's development through Phase 2
- Phase 1 top-line data is still unreported as of mid-2026 (target was H1 2026), which raises questions about whether the data was clean, if safety/tolerability issues emerge, the program could be delayed or terminated
- EDG-15400 is a secondary pipeline asset for Edgewise behind EDG-7500 (HCM), meaning its development timeline and resource allocation may deprioritize it if EDG-7500 requires more resources
- HFpEF is a notoriously difficult indication for drug development, multiple high-profile programs have failed (including Novartis' Entresto struggling in some HFpEF studies), and the condition's heterogeneous patient population makes trial design challenging